OncoMatch/Clinical Trials/NCT05833893
Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma
Is NCT05833893 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies XPO1 inhibitor for nk/t-cell lymphoma.
Treatment: XPO1 inhibitor — Patients with newly diagnosed, pathologically confirmed NK/T-cell lymphoma of stage III-IV treated with XCOPL regimen. 3 weeks for a cycle, with a total of 6-8 cycles.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: allogeneic hematopoietic cell transplant
Lab requirements
Blood counts
WBC ≥ 3.5 x 10^9/L, PLT ≥ 75 x 10^9/L, Hb ≥ 80 g/L
Kidney function
CCr ≥ 60 mL/min
Liver function
AST and ALT ≤ 3.0 ULN; TBIL ≤ 2.0 mg/dL
Normal major organ function, meeting the following definitions: Hematology: WBC ≥ 3.5 x 10 9/L, PLT ≥ 75 x 10 9/L, Hb ≥ 80 g/L; Liver and kidney function: AST and ALT ≤ 3.0 ULN; TBIL ≤ 2.0 mg/dL; CCr ≥ 60 mL/min; liver and kidney function impairment caused by tumor compression is not limited by this; Fibrinogen: normal at first cycle
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify